مقال مراجعة وصول مفتوح
Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma
Systemic chemotherapy has remained the traditional treatment for metastatic non-small-cell lung carcinoma (NSCLC), enhancing survival rate at 1 year to 29%. The median survival had plateaued at around 10 months until early 2008, and in an attempt to enhance survival in advanced disease, maintenance chemotherapy trials …